FILING ANALYSIS · MONDAY, NOVEMBER 9
Definium Therapeutics, Inc. DFTX — 8-K: Results of Operations and Financial Condition
positive
Definium Therapeutics reported positive topline Phase 3 results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder, with approximately $1.05 billion in cash and cash equivalents as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →